Literature DB >> 17322629

Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy.

Fumio Terasaki1, Hiroshi Okamoto, Katsuya Onishi, Akira Sato, Hiroaki Shimomura, Bin Tsukada, Kyoko Imanaka-Yoshida, Michiaki Hiroe, Toshimichi Yoshida, Yasushi Kitaura, Akira Kitabatake.   

Abstract

BACKGROUND: Tenascin-C (TN-C), an extracellular matrix glycoprotein, is specifically expressed at high levels during embryonic development, but not in the adult heart. TN-C reappears at sites of inflammatory tissue remodeling or wound healing under various pathologic conditions, such as acute myocardial infarction, acute myocarditis, and some cases of cardiomyopathy. Therefore, the expression of TN-C might be useful for detecting the clinical characteristics of, and ventricular remodeling in, dilated cardiomyopathy (DCM). METHODS AND
RESULTS: Circulating serum TN-C levels in 107 patients with DCM were measured using an ELISA kit. Clinical data were also assessed by Pearson's or Spearman's correlation analysis to estimate correlations between variables. Serum TN-C levels in DCM patients were higher than those in normal controls (p<0.001). TNC levels showed a significantly positive correlation with New York Heart Association functional class (p<0.001), B-type natriuretic peptide level (p<0.001), cardiothoracic ratio on chest X-ray (p<0.01), left ventricular end-diastolic diameter (p<0.05) and left ventricular end-systolic diameter (p<0.01), and a significantly negative correlation with left ventricular ejection fraction (p<0.01).
CONCLUSIONS: The findings suggest that increased serum TN-C levels indicate the severity of heart failure, left ventricular dysfunction and remodeling in patients with DCM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322629     DOI: 10.1253/circj.71.327

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  29 in total

1.  Impact of surgical ventricular reconstruction for ischemic dilated cardiomyopathy on restrictive filling pattern.

Authors:  Yasuhiro Shudo; Goro Matsumiya; Taichi Sakaguchi; Shigeru Miyagawa; Takashi Yamauchi; Koji Takeda; Shunsuke Saito; Kazuhiro Taniguchi; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-08-12

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 3.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  Tenascin C upregulates interleukin-6 expression in human cardiac myofibroblasts via toll-like receptor 4.

Authors:  Azhar Maqbool; Emma J Spary; Iain W Manfield; Michaela Ruhmann; Lorena Zuliani-Alvarez; Filomena O Gamboa-Esteves; Karen E Porter; Mark J Drinkhill; Kim S Midwood; Neil A Turner
Journal:  World J Cardiol       Date:  2016-05-26

5.  Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Authors:  Marcus Franz; Bernhard R Brehm; Petra Richter; Katja Gruen; Dario Neri; Hartwig Kosmehl; Khosro Hekmat; Andre Renner; Jan Gummert; Hans R Figulla; Alexander Berndt
Journal:  J Mol Histol       Date:  2010-03-16       Impact factor: 2.611

6.  Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.

Authors:  Panagiotis Flevaris; Sadiya S Khan; Mesut Eren; Adam J T Schuldt; Sanjiv J Shah; Daniel C Lee; Sweta Gupta; Amy D Shapiro; Paul W Burridge; Asish K Ghosh; Douglas E Vaughan
Journal:  Circulation       Date:  2017-06-06       Impact factor: 29.690

7.  Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.

Authors:  Marcus Franz; K Grün; P Richter; B R Brehm; M Fritzenwanger; K Hekmat; D Neri; J Gummert; H R Figulla; H Kosmehl; A Berndt; A Renner
Journal:  Histochem Cell Biol       Date:  2010-10-08       Impact factor: 4.304

Review 8.  The Extracellular Matrix in Ischemic and Nonischemic Heart Failure.

Authors:  Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2019-06-20       Impact factor: 17.367

9.  Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome.

Authors:  Nobuo Sakamoto; Yasuto Hoshino; Tomofumi Misaka; Hiroyuki Mizukami; Satoshi Suzuki; Koichi Sugimoto; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-ichi Saitoh; Yasuchika Takeishi
Journal:  Heart Vessels       Date:  2013-03-27       Impact factor: 2.037

10.  B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Authors:  Petra Richter; Markus Tost; Marcus Franz; Annelore Altendorf-Hofmann; Kerstin Junker; Laura Borsi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-27       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.